Methods for treatment and prevention of infectious disease are described. Such infectious diseases may include, for instance, viruses, novel viruses, coronaviruses, and the like. Procedures and protocols for use of various medications, such as typical or atypical antipsychotic medications, to prevent and/or treat infection diseases are presented. Such medications include substances that act as receptor antagonists, partial antagonists, agonists, and/or partial agonists. The medications may specifically include antagonists to dopamine receptors including but not limited to dopamine-2 (D2) receptors and/or serotonin receptors including but not limited to hydroxy-tryptamine receptors.

The invention is directed to an inhalation atomizer comprising a counter and a blocking function. Counter rotates each time the atomizer is actuated. The blocking function includes a first protrusion on the counter and a second protrusion on a lower unit of the atomizer. Once the predetermined number of actuations has been achieved, the first protrusion encounters the second protrusion and prevents further rotation of the counter so that the atomizer is blocked from further use.

The invention is directed to an inhalation atomizer comprising a counter and a blocking function. Counter rotates each time the atomizer is actuated. The blocking function includes a first protrusion on the counter and a second protrusion on a lower unit of the atomizer. Once the predetermined number of actuations has been achieved, the first protrusion encounters the second protrusion and prevents further rotation of the counter so that the atomizer is blocked from further use.

The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.

The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1′):

##STR00001##

and are useful in pharmaceutical compositions, methods or the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1′):

##STR00001##

and are useful in pharmaceutical compositions, methods or the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The disclosure also relates to a method of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) a method of treating cancer, and a method of inhibiting USP28, comprising administering to a subject in need thereof a compound of formula (I).

##STR00001##